At a median follow-up of about 2.5 years, enfortumab vedotin plus pembrolizumab continued to improve progression-free survival and overall survival. First-line treatment with enfortumab vedotin and ...

Treatment with pembrolizumab plus enfortumab vedotin-ejfv resulted in a statistically significant improvement in EFS compared with radical cystectomy surgery alone. Topline results were announced from ...

Promising trial results may be a breakthrough in treatment for cisplatin-ineligible patients with muscle-invasive bladder cancer. In patients with muscle-invasive bladder cancer (MIBC) not eligible ...

A new review was published in Volume 16 of Oncotarget on June 17, 2025, titled "Optimizing enfortumab vedotin plus pembrolizumab therapy." First authors Elias Antoine Karam of the Gustave Roussy and ...

Perioperative enfortumab vedotin plus pembrolizumab demonstrated significant results in a population that represents roughly half of all patients with MIBC, explained Christof Vulsteke, MD, PhD. This ...

Enfortumab vedotin with or without pembrolizumab offers disease control benefits for patients with upper tract urothelial cancer, said Evangelia Vlachou, MD, of Johns Hopkins Medicine. While cisplatin ...

Effect of HER2 IHC on enfortumab vedotin (EV) or EV+pembrolizumab (EVP) benefit in metastatic urothelial carcinoma. Preliminary results from phase II enfortumab vedotin plus toripalimab compared to ...

Differences in patient (pt) characteristics and therapy choice across treatment (tx) groups in locally advanced or metastatic urothelial cancer (la/mUC) in the US: A survey on unmet patient needs.

Pfizer Inc (PFE) announced an update on their ongoing clinical study.

Please provide your email address to receive an email when new articles are posted on . The FDA approved pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph in combination with enfortumab ...

Urothelium is the term for the mucous membrane that lines the urinary tract. This includes the renal pelvis, ureter, urinary bladder and the upper part of the urethra. In the vast majority of cases, ...

The Food and Drug Administration (FDA) has granted Priority Review to enfortumab vedotin-ejfv (Padcev ™) in combination with pembrolizumab (Keytruda ®) as a neoadjuvant treatment and then continued ...